Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (ARTL) recently announced pre-clinical findings suggesting that its fatty acid binding protein 5 (FABP5) inhibitor may effectively reduce anxiety behaviors in key brain areas. These results indicate that FABP5 modulation could serve as a new target for developing anxiety treatments, including potential therapies for post-traumatic stress disorder (PTSD). Published in Cerebral Cortex, the study led by researchers from the University of Western Ontario demonstrates the role of the CB₂ receptor in managing fear and anxiety, underscoring the importance of this research.

Artelo Biosciences (Nasdaq: ARTL) announced advancements in its clinical programs with the CAReS Study for ART27.13, targeting cancer-related anorexia, progressing to a fourth cohort due to its well-tolerated safety profile. The company also reported a net loss of $2.4 million for Q2 2022 and a cash balance of $21.3 million, expected to fund operations into 2023. A 15-for-1 reverse stock split will take effect on August 10, 2022, aimed at enhancing stock marketability and compliance with Nasdaq requirements.

Artelo Biosciences (Nasdaq: ARTL) has initiated the fourth cohort at a 650-microgram dose in its Cancer Appetite Recovery Study (CAReS) for ART27.13, following successful completion of the first three cohorts. The safety review committee reported that ART27.13 was well-tolerated, with no serious adverse events linked to the drug. The Phase 1b trial will help determine the optimal dose before transitioning to a Phase 2a study. ART27.13 targets cannabinoid receptors to address cancer-related anorexia, tapping into a market exceeding $2 billion annually.

Artelo Biosciences (Nasdaq: ARTL) recently presented research at the ICRS Symposium highlighting the effectiveness of its lead compound, ART26.12, in managing chemotherapy-induced pain. Professor Saoirse O’Sullivan reported that ART26.12 demonstrated significant effectiveness in preventing and treating pain sensitivity without sedation, while also mitigating weight loss linked to chemotherapy. The company aims to pursue FDA consultations for ART26.12’s further development. This research opens potential pathways for addressing Chemotherapy-Induced Peripheral Neuropathy, a condition without approved therapies.

Artelo Biosciences (Nasdaq: ARTL) announced that Professor Saoirse O’Sullivan will present pre-clinical data on ART26.12, a fatty acid binding protein 5 inhibitor, at the International Cannabinoid Research Society Symposium on June 26, 2022. Gregory D. Gorgas, the company's CEO, expressed enthusiasm about sharing findings related to advancements in cancer treatment. Additionally, the William A. Devane Young Investigator of the Year Award will be presented at the event, recognizing significant contributions to cannabinoid research.

Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the LD Micro conference on June 7, 2022, at 2:30 PM PT. The event, held at Four Seasons Westlake Village, California, will feature live webcasting and replays available on their site. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, addressing conditions like anorexia, cancer, PTSD, pain, and inflammation. The company emphasizes collaboration with experts and a focus on high-impact therapies.

Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Gorgas is scheduled for an in-person presentation on May 24, 2022, at 5:00 p.m. ET. The event will provide both virtual and in-person participation options, and the presentation will be webcast live, with a replay available. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system.

Artelo Biosciences (NASDAQ:ARLT) will present at the MicroCap Rodeo Spring Into Action - Best Ideas Virtual Investor Conference, scheduled from May 16-20, 2022. CEO Gregory D. Gorgas will speak on May 16, 2022, at 2:00 p.m. ET, with a live webcast available for replay. Artelo focuses on developing therapeutics that modulate lipid-signaling pathways, targeting conditions like cancer and PTSD. Qualified investors can schedule one-on-one meetings for further discussions. For more details, visit www.artelobio.com.

Artelo Biosciences (Nasdaq: ARTL) reported financial and operational results for Q1 2022, maintaining approximately $23.5 million in cash and investments, expected to support operations into late 2023. The net loss increased to $2.0 million or $0.05 per share, compared to $1.7 million or $0.09 per share in Q1 2021. The company anticipates results from the Phase 1b CAReS trial concerning ART27.13, aimed at treating cancer-related anorexia, in Q3 2022. Ongoing collaborations and positive pre-clinical data were highlighted, with a focus on addressing cancer anorexia cachexia syndrome.